Alzheimer 's Disease Medication

Paper Summary:

This paper explains that the Exelon patch is a means of dosing a patient with mild to moderate Alzheimer's disease with rivastigmine, a cholinesterase inhibitor. The author stresses that, based on clinical studies, rivastigmine is not recommended in the treatment of patients with mild to moderately severe Alzheimer's disease. The paper compares the physiology and use of this medication for Alzheimer's disease and Parkinson's dementia.

Table of Contents:
Introduction
Difference between Use for Alzheimer's vs. Parkinson's Dementia
Physiologically Difference of these Two Dementias
Rivastigmine
Advantage of a "Patch
"Moderate" Dementia
Implications of the Health Issue
Circumstances Contributed to this Current Health Care Issue
Implications for Dental Hygienist

From the Paper:

"Treating a patient with Alzheimer's disease with rivastigmine may create false hopes in the caregiver's mind, which affects the economic, social, lifestyle, legal, political, medical and ethical considerations of both patient and caregiver. If the drug, which seems to promise delay of full-time care of a progressive disease, does not deliver this delay, the expectations and therefore the planning of future activities and care are deeply affected. Liability increases on the part of diagnostician, the one prescribing the drug and the administrator."

Sample of Sources Used:

• Activa. (2008). Symptoms of Parkinson's Disease. Activa Deep Brain Stimulation. Retrieved January 20, 2008 from website: http://www.activadbs.com/symptoms.asp.
• Medications and treatment. (2008). Parkinson's Disease Foundation Retrieved January 20, 2008 from website: http://www.pdf.org/AboutPD/med_treatment.cfm.
• NHS. (2005). Holding Statement. National Institute for Clinical Excellence. Retrieved January 20, 2008 from website: http://www.nice.org.uk/nicemedia/pdf/Alzheimer_holdingstatement.pdf.
• NHS. (2007). Final appraisal determination: Donepezil, rivastigmine, galantamine (review) and memantine for the treatment of Alzheimer's disease. Centre Director Report for Guidance Executive. National Institute for Clinical Excellence. Retrieved January 20, 2008 from website: http://www.nice.org.uk/nicemedia/pdf/GE050705AlzFADSignoffReport.pdf.
• Novartis. (2007). Why Exelon patch? Website retrieved January 20, 2008 from http://www.exelonpatch.com/info/treating/exelon/why-exelon-patch.jsp?WT.svl=CM

More papers on Alzheimer 's Disease Medication:

• Cause and Effect Essay # 6501 : "Alzheimer's Disease"
• Essay # 56003 : "Alzheimer's Disease"
• Research Paper # 64199 : "Alzheimer's Disease"

APA Citation:

MLA Citation: